How will payers manage reimbursement of multiple interchangeable biosimilars?
MAC reimbursement: 10%
Generic non-MAC reimbursement rate: 10%
Brand reimbursement rate: 40%
Specialty drug specific rate: 40%
Average Sales Price (ASP): 0%
Average Manufacturer Price (AMP): 0%
National Average Drug Acquisition Cost (NADAC): 0%
In which area could you or your company most benefit from additional training?
Biosimilars and interchangeability requirements: 46.1%
Dynamics that drive PBM and health plan decisions: 15.4%
Various hurdles a prescription must clear before being dispensed: 15.4%
Changing 340B landscape: 15.4%
Flow of funds and prescriptions through the pharmacy channels: 7.7%
Pharmacy chain initiatives and strategy updates: 0%
In the next 5 years, what outcome is most likely for FDA management of accelerated approvals with subsequent failed confirmatory trials?
Status quo with extended review timelines and limited FDA authority: 64%
Legislative change leading to additional FDA authority and actions: 27%
Increased pharmaceutical manufacturer voluntary actions: 9%
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe: